Inicio › Cáncer de ovario › Texas
Ensayos clínicos de Cáncer de ovario en Texas
123 estudios sobre Cáncer de ovario buscan participantes en Texas.
Ciudades en Texas
- Houston90 estudios
- San Antonio31 estudios
- Dallas28 estudios
- Fort Worth17 estudios
- Austin17 estudios
- Tyler7 estudios
- Irving5 estudios
- League City5 estudios
- Abilene4 estudios
- Killeen4 estudios
- The Woodlands4 estudios
Texto oficial del estudio (inglés)
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- NEXT Oncology - San Antonio /ID# 278606, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07278336177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07189871Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- Lyndon Baines Johnson General, Houston
- M D Anderson Cancer Center, Houston
Reclutando
Edades de 18 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT05287451First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06799065A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0103 - University of Texas MD Anderson Cancer Center, Houston
- Site 0203 - Texas Oncology, Tyler
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT05128825Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Houston
- Research Site, Round Rock
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05877599Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Total Women's Care of the Heights, Houston
- Medical Colleagues of Texas, LLP, Katy
ReclutandoEstudio observacional
Edades de 18 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT05051722Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Hendrick Medical Center, Abilene
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Lyndon Baines Johnson General Hospital, Houston
- y 2 más
ReclutandoFase 2
Todas las edades · Todos los sexos · Actualizado el 29 sept 2026 · NCT05564377A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Texas Oncology - Austin Central /ID# 275046, Austin
- Texas Oncology - Fort Worth Cancer Center /ID# 275043, Fort Worth
- Houston Methodist Hospital /ID# 274568, Houston
- y 3 más
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05867251A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Oncology, Austin
- UT Southwestern, Dallas
ReclutandoFase 1
Edades de 19 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06586957DESTINY-PANTUMOUR04
- Research Site, Dallas
ReclutandoEstudio observacional
Edades de 18 a 130 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07124000A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06172478Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Mujeres · Actualizado el 25 sept 2026 · NCT03564340A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Texas Oncology - DFW ( Site 8005), Fort Worth
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 24 sept 2026 · NCT07776691Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
ReclutandoFase 2
Edades de 18 a 130 · Todos los sexos · Actualizado el 23 sept 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- y 1 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Texas Oncology - Abilene - Antilley Road /ID# 277739, Abilene
- Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735, San Antonio
- y 2 más
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 22 sept 2026 · NCT07059845A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07213791A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- USO-Texas Oncology-Central/South Texas, Austin
- UT Southwestern Medical Center, Dallas
- US Oncology, The Woodlands
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07213804Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT05983432Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- M D Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT04038619A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- MD Anderson Cancer Center, Houston
- START Center for Cancer Research, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07109726Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Texas Oncology-Abilene, Abilene
- Jps Health Network, Fort Worth
- The University of Texas Health Science Center Houston, Houston
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 15 sept 2026 · NCT07214779The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- y 2 más
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04585750Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Mujeres · Actualizado el 15 sept 2026 · NCT05739981A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Texas Oncology-Austin Center, Austin
- Texas Oncology-San Antonio Medical Center Pharmacy, San Antonio
- Texas Oncology-Tyler, Tyler
ReclutandoFase 2
Edades de 18 a 99 · Mujeres · Actualizado el 15 sept 2026 · NCT07023627Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Lyndon Baines Johnson General, Houston
- Houston Methodist, Houston
- M D Anderson Cancer Center, Houston
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 14 sept 2026 · NCT04575935ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UT Southwestern Medical Center, Dallas
- DHR Health Advance Care Center, Edinburg
- The Center for Cancer and Blood Disorders, Forth Worth
- y 1 más
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT05059444FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Start Dfw, Fort Worth
- Next Oncology Dallas, Irving
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06303505Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- UT Southwestern Medical Center, Dallas
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 14 sept 2026 · NCT06787612A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06293898A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06400472A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06465069Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- MD Anderson Cancer Center, Houston
- NEXT Oncology, Irving
ReclutandoFase 1
Edades de 18 en adelante · Mujeres · Actualizado el 3 sept 2026 · NCT07755436A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06760819A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Texas Oncology - Central/South Texas ( Site 8009), Austin
- Texas Oncology - DFW ( Site 8001), Fort Worth
- University Of Texas Health Science Center -San Antonio ( Site 0095), San Antonio
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 3 sept 2026 · NCT06824467FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- M. D. Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07216105De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.